« Return to News | Drug Sponsors

Lilly selects Prasco to market generics

Friday, October 28, 2011 11:28 AM

Prasco Laboratories has signed a marketing and distribution agreement with Eli Lilly to market the authorized generic version of ZYPREXA (olanzapine) tablets and ZYPREXA ZYDIS (olanzapine) orally disintegrating tablets, in the U.S.

Prasco will begin distribution of both products upon the first ANDA entrant into the market.  Prasco will market all six strengths of olanzapine tablets. Olanzapine orally disintegrating tablets will be available in four strengths.  The financial terms of the agreement were not disclosed.

“Prasco partnerships with brand companies offer alternatives for consumers and pharmacists that are specific and measurable. This is especially true with the olanzapine launch through our new Lilly relationship,” said Prasco chief executive officer E. Thomas Arington.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.